^
Association details:
| Biomarker: | FAT1 mutation + TP53 wild-type |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Preoperative serum ctDNA predicts early hepatocellular carcinoma recurrence and response to systemic therapies
Published date:
06/08/2022
Excerpt:
Patients preserved FAT1 or LRP1B variants but without TP53 variants had worse progression free survival for receiving lenvatinib combined with immune checkpoint inhibitors after recurrence (HR = 17.1, p < 0.001).
DOI:
10.1007/s12072-022-10348-1
